nabumetone has been researched along with Gastrointestinal Hemorrhage in 16 studies
Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.
nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.
Gastrointestinal Hemorrhage: Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To identify the unbiased differences in the risk of hospitalization with peptic ulcer disease (PUD) or gastrointestinal (GI) hemorrhage among populations using 4 nonsteroidal antiinflammatory drugs (NSAID): nabumetone, Arthrotec, diclofenac plus a cytoprotective agent dispensed separately (diclo+coRx), and naproxen." | 7.73 | Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study. ( Ashworth, NL; Muhajarine, N; Peloso, PM; Stang, M, 2005) |
| "Prespecified analysis of all 8 double-blind, randomized phase 2b/3 rofecoxib osteoarthritis trials conducted from December 1996 through March 1998, including one 6-week dose-ranging study, two 6-week efficacy studies vs ibuprofen and placebo, two 1-year efficacy studies vs diclofenac, two 6-month endoscopy studies vs ibuprofen and placebo, and one 6-week efficacy study vs nabumetone and placebo." | 4.80 | Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. ( Bolognese, JA; Harper, SE; Jensen, DM; Langman, MJ; Quan, H; Simon, TJ; Watson, DJ; Zhao, PL, 1999) |
| "To identify the unbiased differences in the risk of hospitalization with peptic ulcer disease (PUD) or gastrointestinal (GI) hemorrhage among populations using 4 nonsteroidal antiinflammatory drugs (NSAID): nabumetone, Arthrotec, diclofenac plus a cytoprotective agent dispensed separately (diclo+coRx), and naproxen." | 3.73 | Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study. ( Ashworth, NL; Muhajarine, N; Peloso, PM; Stang, M, 2005) |
| " The aim of the present study was to compare nabumetone, a nonacidic drug, with etodolac on rat gastric mucosal damage and prostanoid synthesis, while concurrently measuring prostanoid production during edema formation in a carrageenan model of paw inflammation." | 3.69 | Gastrointestinal irritancy, antiinflammatory activity, and prostanoid inhibition in the rat. Differentiation of effects between nabumetone and etodolac. ( Blower, PR; Durie, M; Gentry, C; Melarange, R; O'Connell, C, 1994) |
| "Repeat oral dosing of nabumetone for 1 month maintains anti-inflammatory efficacy in a carrageenan model of paw oedema yet does not cause gastrointestinal damage." | 3.68 | Anti-inflammatory efficacy and gastrointestinal irritancy: comparative 1 month repeat oral dose studies in the rat with nabumetone, ibuprofen and diclofenac. ( Blower, PR; Gentry, C; Melarange, R; O'Connell, C, 1991) |
| "Nabumetone is a nonacidic nonsteroidal antiinflammatory drug (NSAID) that is effective and appears to cause minimal NSAID gastropathy." | 2.38 | Upper gastrointestinal safety with nabumetone. ( Roth, SH, 1992) |
| "Nabumetone proved to be an effective anti-inflammatory agent that was devoid of gastrointestinal irritancy." | 1.29 | Nabumetone, an effective anti-inflammatory agent, lacks gastrointestinal irritancy in the rat when dosed orally for one month: comparison with tiaprofenic acid and etodolac. ( Blower, PR; Gentry, C; Melarange, R; Spangler, R; Toseland, CD, 1994) |
| "Nabumetone was less potent and less active in inhibiting the production of gastric mucosal 6-keto-PGF1 alpha compared with indomethacin either ex-vivo or in-vitro." | 1.27 | Comparison of the effects of nabumetone with indomethacin on rat gastric mucosal 6-keto-PGF1 alpha production and on bile salt-induced changes in gastric mucosal function. ( Melarange, R; Rashbrook, LC, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (18.75) | 18.7374 |
| 1990's | 9 (56.25) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shi, W | 1 |
| Wang, YM | 1 |
| Li, SL | 1 |
| Yan, M | 1 |
| Li, D | 1 |
| Chen, BY | 1 |
| Cheng, NN | 1 |
| Ashworth, NL | 1 |
| Peloso, PM | 1 |
| Muhajarine, N | 1 |
| Stang, M | 1 |
| Hayllar, J | 1 |
| Bjarnason, I | 1 |
| Melarange, R | 4 |
| Gentry, C | 3 |
| Blower, PR | 3 |
| Toseland, CD | 1 |
| Spangler, R | 1 |
| Voss, GD | 1 |
| Schweitzer, P | 1 |
| Durie, M | 1 |
| O'Connell, C | 2 |
| Lanza, FL | 1 |
| Langman, MJ | 1 |
| Jensen, DM | 1 |
| Watson, DJ | 1 |
| Harper, SE | 1 |
| Zhao, PL | 1 |
| Quan, H | 1 |
| Bolognese, JA | 1 |
| Simon, TJ | 1 |
| Chan, FK | 1 |
| Sung, JJ | 1 |
| Ching, JY | 1 |
| Wu, JC | 1 |
| Lee, YT | 1 |
| Leung, WK | 1 |
| Hui, Y | 1 |
| Chan, LY | 1 |
| Lai, AC | 1 |
| Chung, SC | 1 |
| Basson, MD | 1 |
| Panzini, L | 1 |
| Palmer, RH | 1 |
| Huskisson, EC | 1 |
| Roth, SH | 1 |
| Rashbrook, LC | 1 |
| Lussier, A | 2 |
| Davis, A | 1 |
| Lussier, Y | 1 |
| Lebel, E | 2 |
3 reviews available for nabumetone and Gastrointestinal Hemorrhage
| Article | Year |
|---|---|
Gastrointestinal toxicity of newer NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Etodolac; Gastrointestinal Hemorrhage; Humans; N | 1993 |
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cyclooxyg | 1999 |
Upper gastrointestinal safety with nabumetone.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Butanones; Chromium Radioisotopes; Clinical Trials | 1992 |
4 trials available for nabumetone and Gastrointestinal Hemorrhage
| Article | Year |
|---|---|
Randomized trial of low-dose misoprostol and naproxen vs. nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of non-steroidal anti-inflammatory drugs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Drug Therapy, Co | 2001 |
Effect of nabumetone and aspirin on colonic mucosal bleeding time.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy; Butanones; Co | 2001 |
Comparative gastrointestinal blood loss associated with placebo, aspirin, and nabumetone as assessed by radiochromium (51Cr).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Butanones; Chromium Radioisotopes; Double-B | 1989 |
Radiochromium (chromium-51) evaluation of gastrointestinal blood loss associated with placebo, aspirin, and nabumetone.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Butanones; Chromium Radioisotopes; Double-B | 1987 |
9 other studies available for nabumetone and Gastrointestinal Hemorrhage
| Article | Year |
|---|---|
Risk factors of adverse drug reaction from non-steroidal anti-inflammatory drugs in Shanghai patients with arthropathy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheu | 2004 |
Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cohort Studies; Databas | 2005 |
NSAIDs, Cox-2 inhibitors, and the gut.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cyclooxygenase Inhibitors; Digestive Sy | 1995 |
Nabumetone, an effective anti-inflammatory agent, lacks gastrointestinal irritancy in the rat when dosed orally for one month: comparison with tiaprofenic acid and etodolac.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Butanones; Carr | 1994 |
GI bleeding associated with nabumetone.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Gastrointestinal Hemorrhage; Humans; Male; | 1994 |
Gastrointestinal irritancy, antiinflammatory activity, and prostanoid inhibition in the rat. Differentiation of effects between nabumetone and etodolac.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cecum; De | 1994 |
NSAIDs for the new decade--nabumetone?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Gastrointestinal Hemorrha | 1991 |
Anti-inflammatory efficacy and gastrointestinal irritancy: comparative 1 month repeat oral dose studies in the rat with nabumetone, ibuprofen and diclofenac.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Butanones; Carrageenan; Diclofenac; E | 1991 |
Comparison of the effects of nabumetone with indomethacin on rat gastric mucosal 6-keto-PGF1 alpha production and on bile salt-induced changes in gastric mucosal function.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bile Acids and Salts | 1987 |